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Background
• Chimeric antigen receptor (CAR) T-cells are genetically engineered
immune cells commercially available to treat B-cell lymphoma.
• After CD19 CART treatment, half of patients relapse within 6 months due
to downregulation of the CD19 antigen and tumor resistance, leading to a
need to develop novel treatments.3
• Developing new therapies is a process that takes years. The FDA
requires the development history to be summarized in a document called
a Target Product Profile (TPP). A TPP is a live document following a drug
from preclinical to commercial that collects all its clinical and
production information.
• The development of any new therapy starts with a risk-benefit approach
(Figure 1), followed by the actual development of the drug (Figure 2).
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Figure 3. Components of the clinical and production sections of the novel target CAR T-cell Target Product Profile (TPP).1

Apheresis

Collected Tcells

Construction of a TPP

Figure 1. FDA assessment of a drug depends on the balance of risks and benefits..2,4

The TPP is a live document that follows a drug through its development process
and records all relevant information.
• The TPP contains both clinical and drug development/production information.
• Clinical information includes indications, patient eligibility criteria, dosing and
pre-treatment conditioning, expected adverse reactions, and pharmacology.
• Drug development covers CART and lentivirus production, as well as analytics
and release testing. Production logistics are also included.
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Figure 2. Process of developing, manufacturing, and releasing a biologic drug at MD Anderson.

Met with each team member to compile information.
Observed the laboratory steps in the development process.
Conducted a literature review of CAR T cell therapy research to provide a description
of pharmacology, likely adverse reactions, contraindication, and drug interactions.
Collected information about upcoming dose escalation and expansion clinical trial,
release testing and qualification requirements, and clinical procedure.
Constructed a detailed process description.
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Figure 4. Procedures for CAR T-cell treatment. The patient is selected from eligibility criteria and
conditioned, while T-cells are collected, genetically modified, and infused back into the patient.

The Clinical Product – Result of the TPP
Manufacturing Procedure
1. Autologous T-cells are collected through apheresis.
2. T-cells are isolated through immunomagnetic cell separation.
3. T-cells are activated with antibodies and IL-2.
4. T-cells are transduced with a lentiviral vector to express the
intended CAR.
5. CAR T-cells are expanded with media and IL-2 for 2-3 days until
dose level is reached.
6. CAR T-cells are harvested and cryopreserved.
Clinical Procedure
1. Patient undergoes leukapheresis.
2. Patient receives chemotherapy conditioning to deplete the
immune system and allow space for CAR T-cells to proliferate.
3. Patient receives a single infusion of a fixed dose of CAR T cells.
4. Patient is monitored daily for two weeks after infusion.
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